According to our results, naringenin did not directly target PCSK9, but it has been reported that it stimulated LDLR (an interacting protein of PCSK9) expression by increasing the phosphorylation of phosphatidylinositol-3 kinase and extracellular signal-regulated protein kinase 1/2, thereby effectively reducing the mortality and morbidity rate of coronary heart disease (Bawazeer et al., 2017). The gene discussed is LDLR; the disease is coronary artery disorder.